Table of contents

• Trial overview
• Who participates
• What is measured
• Study design and treatment groups
• Main endpoints and time points
• Key points for patients

Trial overview

This authorised Phase 2 study is an interventional trial, which means participants receive study vaccines so researchers can measure the effects.^[1] The study has 750 planned participants and focuses on meningococcal immunization in healthy children, toddlers, and infants.^[1]

The trial title says it is a study of the safety and immunogenicity of an investigational pentavalent meningococcal ABCYW vaccine in children, toddlers, and infants.^[1] In the brief summary, the main goals are to describe the safety profile of the MenPenta vaccine formulations and the immune response after vaccination in the different age groups.^[1]

Who participates

The study includes healthy children, toddlers, and infants.^[1] The brief summary divides the study into stages: Stage 1 for children, Stage 2 for toddlers, and Stage 3 for infants.^[1]

For infants, the summary describes vaccination at about 4 months of age for the second dose and at 12 to 15 months of age for the third dose.^[1] This helps researchers see how the immune response changes over time in very young children.^[1]

What is measured

The main safety outcomes include unsolicited immediate adverse events, solicited injection site reactions, systemic reactions, unsolicited adverse events, and serious adverse events.^[1] In simple terms, this means the study watches for any health problems after vaccination, including local reactions at the injection site and more serious medical events.^[1]

The immune response outcomes use blood tests such as hSBA, which is a test that checks whether antibodies can help kill meningococcal bacteria.^[1] The trial measures antibody titers, seroresponse, and geometric mean titers against meningococcal serogroups A, C, W, Y, and reference MenB strains.^[1]

Researchers also measure the percentage of participants with antibody levels at or above the lower limit of quantification, which is the lowest level the test can measure reliably.^[1] These measurements are taken in infants, children, and toddlers at the time points listed in the protocol.^[1]

Study design and treatment groups

The intervention list shows several vaccines used in the study, including MenPenta SD, MenPenta fHD, and comparator vaccines such as Hexyon, MenQuadfi, Bexsero, Prevenar 13, RotaTeq, and Nimenrix.^[1] The brief summary says the trial compares the MenPenta vaccine formulations with comparator vaccines in healthy participants.^[1]

The source data do not give full randomization details, but they do show that the trial is designed to compare safety and immune response across age groups and vaccine formulations.^[1] The study is authorised, which means it has been approved to proceed.^[1]

Main endpoints and time points

In infants, one key endpoint is the immune response 30 days after the second dose and again after the third dose.^[1] The trial measures antibody titers, seroresponse, geometric mean titers, and the share of participants with measurable antibody levels for serogroups A, C, W, Y, and MenB reference strains.^[1]

In children and toddlers, the study measures the same kinds of immune outcomes at the time points listed in the protocol, including after vaccination and at follow-up points.^[1] This lets researchers compare how well the vaccine works in different age groups.^[1]

The trial also records the number of participants with serious adverse events, which are important medical problems that need special attention.^[1] Together, these endpoints show whether the vaccine is tolerated and whether it triggers a measurable immune response.^[1]

Key points for patients

• The study is focused on meningococcal disease prevention research in young age groups, not on adults.^[1]

• It includes healthy children, toddlers, and infants, so the trial is looking at vaccine response in early life.^[1]

• Researchers are checking both safety and immune response, which are the two main goals of the study.^[1]

• The trial uses blood tests to see whether the body makes antibodies after vaccination.^[1]

• The study is authorised and plans to include 750 participants.^[1]